van Herpen, C. M., Agarwala, S. S., Hauschild, A., Berking, C., Beck, J. T., Schadendorf, D., . . . Dummer, R. (2019). Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma. Oncotarget.
Citação norma Chicagovan Herpen, Carla M.L., et al. "Biomarker Results From a Phase II Study of MEK1/2 Inhibitor Binimetinib (MEK162) in Patients With Advanced NRAS- or BRAF-mutated Melanoma." Oncotarget 2019.
Citação norma MLAvan Herpen, Carla M.L., et al. "Biomarker Results From a Phase II Study of MEK1/2 Inhibitor Binimetinib (MEK162) in Patients With Advanced NRAS- or BRAF-mutated Melanoma." Oncotarget 2019.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.